Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma

Although resistance to poly(ADP‐ribose) polymerase inhibitors (PARPi) has gradually become a major challenge in the maintenance therapy for high‐grade serous ovarian carcinoma (HGSOC), there are no universal indicators for resistance monitoring in patients. A key resistance mechanism to PARPi is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Dianxing, Guo, Ensong, Yang, Bin, Qin, Xu, Fu, Yu, Fan, Junpeng, Zhuang, Xucui, Yao, Qianqian, Lu, Funian, Li, Wenting, Xiao, Rourou, Wu, Xue, Yang, Xiaohang, Wang, Zizhuo, Liu, Chen, You, Lixin, Zang, Rongyu, Zhou, Qi, Zhao, Weidong, Chen, Gang, Sun, Chaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357630/
https://www.ncbi.nlm.nih.gov/pubmed/35661486
http://dx.doi.org/10.1111/cas.15456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357630/
https://www.ncbi.nlm.nih.gov/pubmed/35661486
http://dx.doi.org/10.1111/cas.15456

Ejemplares similares